Stay updated on PLACARD Trial: CXD101 + Pembrolizumab in DLBCL
Sign up to get notified when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.

Latest updates to the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page
- Check5 days agoChange DetectedFooter updated to display Revision: v3.3.3; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedRevision: v3.3.2 is displayed, replacing v3.3.1. No substantive study information appears to have changed.SummaryDifference0.1%

- Check34 days agoChange DetectedRevision: v3.3.1 was added and Revision: v3.2.0 was removed, a metadata update with no change to trial content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check41 days agoChange DetectedThe government funding/operating status notice was removed from the page. This does not affect the study details, eligibility criteria, or trial timelines.SummaryDifference0.4%

- Check55 days agoChange DetectedBoth screenshots show the same study details and status; there are no additions or deletions to core content such as the trial title, conditions, eligibility, or outcomes.SummaryDifference0.4%

- Check84 days agoChange DetectedCore page content updated with a government operating status notice and a new resource topic; software revision updated from v3.1.0 to v3.2.0. No other significant changes.SummaryDifference3%

Stay in the know with updates to PLACARD Trial: CXD101 + Pembrolizumab in DLBCL
Enter your email address, and we'll notify you when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.